LGALS3 and congestive heart failure: A head-to-head comparison study with Gal-3 in patients with chronic heart failure also demonstrated that sST-2 performed better than Gal-3 and could predict 5-year risk of cardiovascular death (Bayes-Genis et al., 2014).